Dark Horse Consulting Group and KunTuo Medical Research and Development have signed a Memorandum of Understanding to establish a strategic collaboration providing biotherapeutics developers with an integrated pathway for conducting clinical trials in China. The partnership combines DHCG's regulatory and consulting expertise with KunTuo's clinical research capabilities and resources across China, aiming to accelerate cell and gene therapy development and reduce delays in trial initiation.

Following a market rally driven by US-Iran peace deal hopes and strong tech earnings, eight underperforming US stocks are identified as having significant upside potential of 25-85%. While the S&P 500 and NASDAQ reached record highs, certain stocks have fallen 10-20% over two weeks despite strong fundamentals. IQVIA and Sonoco are highlighted as examples of beaten-down stocks trading well below fair value estimates with analyst upside targets of 20-97%.

Eli Lilly's stock dropped nearly 4% on Friday following disappointing early prescription data for its newly FDA-approved weight-loss pill Foundayo. The drug recorded only 3,707 prescriptions in its second week, significantly trailing competitor Novo Nordisk's Wegovy pill which had 18,410 prescriptions in its second week. While Lilly cautioned that weekly data may not be comprehensive, the sluggish start raises concerns despite the company's strong overall portfolio.

The clinical trial management system (CTMS) market is experiencing significant growth, expanding from $2.25 billion in 2025 to $2.54 billion in 2026 at a 13.1% CAGR, with projections reaching $4.2 billion by 2030. Growth is driven by increasing global clinical trials, adoption of cloud-based platforms, AI-powered analytics, and decentralized trial models. Key players are making strategic moves including platform launches and acquisitions to enhance technological capabilities.

The AI clinical trial protocol feasibility tool market is experiencing rapid expansion, growing from $0.83 billion in 2025 to $1.06 billion in 2026 with a 27.3% CAGR. The market is projected to reach $2.76 billion by 2030, driven by increasing protocol complexity, precision medicine focus, decentralized trial designs, and AI-enabled protocol optimization. Key players include IQVIA Holdings, SAS Institute, Veeva Systems, and Tempus AI, with North America leading and Asia-Pacific emerging as the fastest-growing region.

The clinical trial data visualization market is projected to grow from $0.89 billion in 2025 to $1.82 billion by 2030 at a CAGR of 15.4%, driven by increasing adoption of AI-powered solutions, cloud-based platforms, and decentralized trials. Major players include ICON plc, Oracle Corporation, and IQVIA Inc., with Asia-Pacific emerging as the fastest-growing region.

The AI-based clinical trial solution providers market is experiencing rapid growth, expanding from $3.03 billion in 2025 to $3.72 billion in 2026 with a projected CAGR of 23%, reaching $8.53 billion by 2030. Key drivers include AI-optimized patient recruitment, cloud-based platforms, decentralized trials, and regulatory compliance automation. North America leads the market while Asia Pacific shows fastest growth.

The eCOA, eSource, and clinical trials market is projected to grow from $51.15 billion in 2025 to $81.46 billion by 2030 at a 9.8% CAGR, driven by AI adoption, decentralized trial models, and digital transformation. Key growth factors include regulatory acceptance of electronic records, cloud-based systems, and real-time data capture. Despite tariff challenges, regional software development is strengthening market resilience.

The drug development services market is projected to grow from $28.09 billion in 2025 to $50.26 billion by 2030 at a CAGR of 12.4%, driven by increased R&D investments, AI adoption, personalized medicine, and emerging market expansion. Key growth areas include preclinical research, regulatory optimization, and cloud-based data management, with precision medicine and genomics advancements playing pivotal roles.

Charles River Laboratories announced significant divestiture plans, selling its CDMO and Cell Solutions businesses to GI Partners, and certain European Discovery Services assets to IQVIA Holdings. The divestitures will reduce 2026 revenue by over $200 million but are expected to improve adjusted operating margins by at least 100 basis points and add approximately 10 cents to adjusted EPS. The company raised its fiscal 2026 adjusted earnings guidance to $10.80-$11.30.

The global pharmacovigilance market is projected to grow from USD 8.91 billion in 2025 to USD 24.69 billion by 2035, at a CAGR of 10.34%. Growth is driven by stringent regulatory requirements, increased adverse drug reaction incidents, and pharmaceutical industry expansion into emerging markets. The U.S. market alone is expected to reach USD 9.48 billion by 2035. Phase IV post-market surveillance and contract outsourcing services dominate the market segments.

The global clinical trials support software solutions market is valued at USD 14.31 billion in 2026 and is expected to reach USD 34.15 billion by 2035, growing at a 10.15% CAGR. North America leads the market while Asia Pacific shows the fastest growth. CTMS solutions dominate by product type, cloud-based delivery leads, and CROs lead by end-user segment. Key growth drivers include increasing clinical trial complexity, adoption of decentralized trials, AI-driven analytics, and regulatory compliance demands.